Chimerix (NASDAQ:CMRX) Stock Slips To a New Low Following Smallpox Drug Deal

May 17, 2022

The smallpox medicine had been the only product from Chimerix (NASDAQ:CMRX) that had managed to get approval from the United States Food and Drug Administration. However, the company announced yesterday that it had decided to sell the product in a deal that is going to be worth as much as $337.5 million. Trading Data On Monday, CMRX stock plunged 61% to $1.66 with more than 38.01 million shares, compared to…